Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18663392 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2ESR1ESR2QDPR | |
| SCHEMBL4612359 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2ESR1ESR2QDPR | |
| SCHEMBL6539105 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2ESR1ESR2QDPR | |
| SCHEMBL5077540 | 0.70 | SMN1; SMN2 (0.46) | SMN1; SMN2ESR1ESR2QDPR | |
| SCHEMBL1065980 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2ESR1ESR2QDPR | |
| SCHEMBL28874397 | 0.69 | RAB9A (0.36) | SMN1; SMN2 | |
| SCHEMBL28785854 | 0.68 | CRHBP (0.34) | — | |
| SCHEMBL2720984 | 0.65 | ESR1 (0.56) | SMN1; SMN2ESR1ESR2QDPR | |
| Hydrogen Sulfide SCHEMBL22229827 | 0.65 | MMP3 (0.39) | SMN1; SMN2ESR1ESR2QDPR | |
| Hydroquinone SCHEMBL28278112 | 0.60 | CA1 (0.53) | EGFRFBP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608233-B2 | Nitrating a bis(4-hydroxyphenyl) bonded to each other or through an electron-donating bridging group, sulfoxide, sulfone or carbonyl group using nitric acid in a solvent and free from other acids | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030055288-A1 | Process for producting bis(4-hydroxy-3-nitrophenyl) compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2003-03-20 | — | — | US | disclosed |
| EP-1277727-A1 | PROCESS FOR PRODUCING BIS(4-HYDROXY-3-NITROPHENYL) COMPOUND | Nippon Kayaku Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0895985-A2 | Method for producing bis(3-amino-4-hydroxyphenyl) compounds | Nippon Kayaku Kabushiki Kaisha (JP) | 1999-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055288-A1 | Process for producting bis(4-hydroxy-3-nitrophenyl) compound | NOS3, NOS2, NOS1 | SMN1; SMN2 979/4885EGFR 3916/4885FBP1 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.